Nebenwirkungen · Evenity
EVENITY 105 mg solution for injection in pre-filled pen EVENITY 105 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 5
HOS-139545 · Präparat HOS-098368
The most common adverse reactions were nasopharyngitis (13.6%) and arthralgia (12.4%). Hypersensitivity-related reactions occurred in 6.7% of patients treated with romosozumab. Hypocalcaemia was reported uncommonly (0.4% of patients treated with romosozumab). In randomised controlled studies, an increase in serious cardiovascular events (myocardial infarction and stroke) has been observed in romosozumab treated patients compared to controls (see section 4.4 and information below).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-07T15:31:00Z · SHA-256 350bccbdb1daac02b4a8386e742b9e66b7f3704c090c59a51d1856d298cfde74 · Passage 73740270206a6698ab4c6aa135fcd49f5870bbabb33fe21da8d8f3f9c542d918 · Zeichen 31–516 im Abschnitt